Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

Last updated: October 6, 2021
Sponsor: Meshalkin Research Institute of Pathology of Circulation
Overall Status: Active - Recruiting

Phase

4

Condition

Circulation Disorders

Treatment

N/A

Clinical Study ID

NCT05073094
BETABLOCK-21
  • Ages > 18
  • All Genders

Study Summary

Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac surgery to reduce the rate of cardiovascular complications. Several randomized-controlled studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No studies assessed the influence of esmolol in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac surgery.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age > 18 years
  • Signed informed consent
  • Patient with hypertrophic obstructive cardiomyopathy undergoing surgery undercardiopulmonary bypass

Exclusion

Exclusion Criteria:

  • History of adverse effects on esmolol
  • Urgent/emergent surgery
  • Administration of esmolol in 30 days before randomization
  • Participation in other randomized trial during same hospitalization

Study Design

Total Participants: 80
Study Start date:
October 06, 2021
Estimated Completion Date:
July 01, 2023

Connect with a study center

  • E. Meshalkin National Medical Research Center

    Novosibirsk,
    Russian Federation

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.